Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene <i>RGS19</i> (regulator of G protein signaling 19) in bladder cancer

Bladder cancer is one of the most severe genitourinary cancers, causing high morbidity worldwide. However, the underlying molecular mechanism is not clear, and it is urgent to find target genes for treatment. G-protein-coupled receptors are currently a target of high interest for drug design. Thus, we aimed to identify a target gene-related to G-protein-coupled receptors for therapy. We used The Cancer Genome Atlas (TCGA) and DepMap databases to obtain the expression and clinical data of <i>RGS19</i>. The results showed that <i>RGS19</i> was overexpressed in a wide range of tumor, especially bladder cancer. We also explored its effect on various types of cancer. High expression of <i>RGS19</i> was also shown to be significantly associated with poor prognosis. Cell models were constructed for cell cycle detection. sh<i>RGS19</i> can halt the cell cycle at a polyploid point. <i>RGS19</i> is a G-protein-coupled receptor signaling pathway-related gene with a significant effect on survival. We chose <i>RGS19</i> as a therapeutic target gene in bladder cancer. The drug GSK1070916 was found to inhibit the effect of <i>RGS19</i> via cell rescue experiments <i>in vitro</i>.